Drug Trial Radar · NCT04603976
Registry for Migraine - Clinical Core
Last checked: Nov 20, 2026Latest source record: Oct 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 25, 2020
Primary completion
Oct 2022
Study completion Oct 2022
Sponsor
- Lead sponsor
- Danish Headache CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.
Conditions
- Migraine
Interventions
ErenumabDrug
Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Headache DiaryTime frame: Baseline Phase (Day -28 to Day 1) to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Danish Headache Center
Glostrup Municipality, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.